UroGen Pharma (URGN) Misses Q2 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Goldman Sachs Reiterates Neutral Rating on UroGen Pharma (URGN)
August 13, 2024 4:09 PM EDTGoldman Sachs analyst Paul Choi reiterated a Neutral rating and $22.00 price target on UroGen Pharma (NASDAQ: URGN).
The analyst comments "Jelmyto sales flat y/y as focus remains on completing the rolling NDA submission for UGN-102. URGN reported its 2Q24 results... More
